Bacillus Spore Probiotics for Bloating: What Trials Show

Spore survival is real. Symptom relief remains unproven.

Bacillus probiotics have a practical advantage over many conventional probiotic products: they form dormant spores that can survive acid, heat, and storage, then germinate under favorable intestinal conditions. That makes strains such as Bacillus subtilis MB40 and DE111 appealing on paper. A probiotic cannot affect the gut if it never arrives alive.

But delivery is not treatment. The best direct human test of MB40 for bloating failed its pre-specified primary endpoints in the full study population. Evidence for DE111, Bacillus clausii CSI08, and Bacillus megaterium MIT411 is earlier still. The sensible conclusion is narrower than the marketing: Bacillus spores are a plausible probiotic delivery platform, but these strains do not yet have convincing clinical evidence for bloating or functional gastrointestinal symptoms.

Why Bacillus spores attract attention

Most familiar probiotics are delivered as living, metabolically active cells. Spore-forming Bacillus species package themselves differently: in a dormant, highly resistant form that can tolerate harsh conditions before germinating later. In a 2021 simulated gastrointestinal-survival study, commercial spore-forming probiotics maintained viability through conditions that were hard on conventional vegetative strains.

That finding supports biological plausibility, not clinical benefit. It came from an in vitro model, not people, and it did not test MB40 specifically. No human fecal-recovery study in the available published evidence confirms that MB40 reaches the intestine, persists there, or does so at a biologically active concentration. A spore can clear the stomach and still fail to change bloating, pain, stool pattern, or quality of life.

The same boundary applies to claims about "germination metabolomics" or anti-inflammatory lipokines. Those ideas may sound suitably microbiome-shaped, but the studies discussed here do not provide primary evidence for either claim. They should not be used to sell a clinical effect.

The key MB40 trial: null primary outcomes

The central trial was a randomized, double-blind, placebo-controlled trial of B. subtilis MB40. It enrolled 100 adults with functional bloating, gas, and abdominal discomfort, assigned MB40 or placebo for four weeks, and used 5 × 10⁹ CFU per day.

In the full randomized population, MB40 did not produce statistically significant between-group differences in any pre-specified primary symptom outcome: bloating intensity, days with bloating, abdominal discomfort, or gas. This is the result that should drive the interpretation. It tests the product against placebo in the population the trial set out to study.

The publication also reported within-group improvements from baseline in the MB40 group for several quality-of-life measures: role limitation from physical problems (p=0.026), vitality (p=0.034), and social functioning (p=0.037). Those comparisons do not establish that MB40 outperformed placebo. Symptoms and quality-of-life scores often improve during a trial for reasons that include regression to the mean, expectation, natural fluctuation, and study participation itself. The relevant question is whether the treatment group improved more than the placebo group on the planned endpoint. For the primary outcomes, it did not.

The male subgroup is a lead, not an answer

The MB40 paper reported numerical advantages in a male subgroup: a 1.38-point lower bloating-intensity score, 1.32 fewer days with bloating, 1.06 fewer days with gas, 86 fewer minutes of gas, 1.32 fewer days of abdominal discomfort, and a 1.02-point lower diarrhea score versus placebo. Those numbers could justify a better trial. They cannot justify a recommendation.

The reported subgroup results include no p-values or confidence intervals, so readers cannot assess their precision or statistical significance. The treatment subgroup was estimated to contain about 25 men, far too few to support a dependable subgroup conclusion. The available publication also does not establish that the male analysis was pre-specified. When a trial misses its primary endpoints and a small subgroup later looks favorable, chance is a serious alternative explanation.

A plausible mechanism and an intriguing subgroup signal are reasons to run another trial. They are not evidence that the product works for the person holding the bottle.

DE111, CSI08, and MIT411 have thinner clinical records

B. subtilis DE111 is often presented as a benchmark Bacillus probiotic. A 2021 narrative review of DE111 describes its spore-forming biology and discusses gastrointestinal and immune-related properties. A narrative review can organize rationale, but it does not add a powered, placebo-controlled bloating trial. It provides no primary endpoint evidence that DE111 relieves bloating in adults.

A 2023 randomized, double-blind, placebo-controlled pilot trial evaluated CSI08, MIT411, and a multi-strain Bacillus cocktail that included DE111 for gastrointestinal health outcomes. The study contributes useful controlled safety and feasibility information, but its pilot design was not powered to establish efficacy. The cocktail arm also cannot identify which strain, if any, produced an observed effect. A blend can be useful commercially; it is awkward scientifically when the question is which organism works.

The MB40 trial reported no concerning safety signal across its biometric and hematological measures. That is reassuring for four weeks in that study population, but it does not answer questions about long-term use, durable colonization, or symptom benefits.

Why a positive trial in another Bacillus species does not settle the question

A 2023 double-blind, placebo-controlled trial of Bacillus coagulans MTCC 5856 studied functional gas and bloating in adults. It is relevant because it tests a spore-forming Bacillus in a similar clinical area. It is not evidence that MB40, DE111, CSI08, or MIT411 works.

B. coagulans and B. subtilis are distinct species, with different genomes, metabolic behavior, and host interactions. Probiotic evidence is strain-specific even within a species; it does not become transferable simply because two organisms form spores. The available account of the MTCC 5856 study also does not provide extractable effect sizes that would allow a meaningful comparison with MB40's reported male-subgroup estimate.

For the broader IBS landscape, a 2025 Lancet Gastroenterology & Hepatology network meta-analysis of dietary interventions did not include a B. subtilis strain in its evidence hierarchy. Absence from a synthesis is not proof that an intervention fails. It does fit the more basic problem: no replicated, adequately powered, primary-endpoint-positive trial establishes a Bacillus subtilis strain as a treatment for bloating or IBS-related symptoms.

What a convincing trial would need

The next study should not merely repeat the format with better adjectives. It should pre-register its outcomes and subgroup analyses, enroll at least 200 participants, report confidence intervals and full between-group results, include both sexes, and test whether dose matters. Independent funding and replication by another group would make a positive result much easier to trust. Human fecal-recovery work could separately test the proposed delivery advantage for MB40 rather than assuming it from related spores or laboratory models.

Until then, the practical verdict is straightforward. Do not choose MB40 for bloating on the strength of a failed full-population trial and an unverified small male subgroup. Treat CSI08 and MIT411 as early-stage candidates supported by pilot safety and feasibility data, not established symptom treatments. Bacillus spores may prove useful, but the current evidence shows a good delivery hypothesis—not reliable relief for bloating.